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Thi s  discussion concerns  amebias i s  in  the 
t empe ra t e  p o r t i o n  of tim U n i t e d  States. 
T h e r e  is rea l ly  no subs t an t i a l  q u a l i t a t i v e  
difference be tween  the b e h a v i o r  of t i le 
ameba  in the  t ropics  as c o m p a r e d  w i th  the  
behav ior  of amebae  in t e m p e r a t e  c l imates .  
T h e r e  is a q u a n t i t a t i v e  d i~e rence  in the  
express ion of the wtr ious  syndromes  in  these 
two env i ronmen t s .  A h n o s t  every ca re fu l ly  
pe r fo rmed  e p i d e m i o l o g i c  survey in the  
U n i t e d  States shows an  inc idence  of  Ent- 
~,meba hislol),tic~ in fec t ion  wh ich  exceeds 
2°'~, (1). T h e r e  is an a d d i t i o n a l  1 - 2 %  
infect ion  wi th  Entameba hartrnannii a n d  
an a d d i t i o n a l  b a c t i o n  of a pe rcen t  inci-  
dence of the  o the r  p ro tozoan  o rgan i sms  
which can infect  the  i n t e s t i na l  tract .  Mos t  
of the E histol),tica in fec t ions  in  o u r  en- 
v i r o n m e n t  are s i lent  or  ca r r i e r  infect ions .  
Occasional ly ,  the a m e h a  finds a vehic le  for 
express ion  of itself. T h i s  is usua l ly  a dra- 
mat ic ,  local ized o u t b r e a k  of ep idenl ic ,  
fu lminan t ,  in tes t ina l  and  systemic amebi -  
asis. In te res t ing ly ,  in a l l  of these e p i d e m i c  
ou tb reaks  there  is good  ev idence  of water-  
borne  sewage c o n t a m i n a t i o n .  T h i s  discov- 
ery carries tile i n t e re s t ing  i m p l i c a t i o n  tha t  
the 5% genera l  inc idence  of p ro tozoan  
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paras i tes  which  we f ind in  an e p ide mio log -  
ic survey represen ts  a r e l a t ive ly  cons tan t  
b reach  of e n v i r o n m e n t a l  hygiene.  
In  an  e p i d e m i c  o u t b r e a k  of disease 
whe re in  we assume tha t  there  is a s ingle 
s t ra in  of v i r u l e n t  pa ras i t e  which  is oper-  
at ive,  tile r a t io  of c l in ica l  i l lness to ca r r i e r  
s tate is stil l  r e m a r k a b l y  low. T i l e  best  illus- 
t r a t i on  of this is the o u t b r e a k  of amebias i s  
tha t  occur red  in South  Bend,  I n d i a n a  (2). 
A careful  e p i d e m i o l o g i c  s tudy of the  g r o u p  
at r isk was ca r r i ed  out.  T h e r e  were 800 
isolates of E histol),tica a m o n g  the popu la -  
t ion of South  Bend  tha t  cou ld  have  been  
affected, b u t  only  31 c l in ica l  cases of amebi -  
asis. T h e r e  were 2 l iver  abscesses a n d  4 
dea ths  in tha t  p a r t i c u l a r  ep idemic ,  hence  
the impre s s ion  tha t  the  r a t i o  of c l in ica l  
disease to ca r r i e r  state is low even wi th  a 
v i r u l e n t  paras i te .  
I n  a d d i t i o n  to e p i d e m i c  exper ience ,  we 
observe  tile s teady b u t  i n f r e q u e n t  appea r -  
ance of s ingle cases of  c l in ica l ly  s igni f icant  
systemic amebias is ,  u sua l ly  l iver  abscess. 
T h e s e  are t ru ly  i n d i g e n o u s  cases. T h e y  
t u rn  up at the  U n ive r s i t y  of M i c h i g a n  at  
the ra te  of a b o u t  one a year.  T h e  last  one  
we h a d  was a 25-year-old m u s i c i a n  f rom the 
A n n  A r b o r - Y p s i l a n t i  area  wlto p re sen ted  
wi th  weight  loss, r i gh t  u p p e r  q u a d r a n t  dis- 
comfor t  and  n i g h t  sweats. His  on ly  h i s tory  
of t ravel  was a visi t  to N e w  York  State.  H e  
had  not  been ou t  of  the c oun t ry  or  to the  
S o u t h e r n  U n i t e d  States. His  i l lness was 
p ro longed ,  and  at  the  t ime  he was seen, he 
had  been  sick for 3 months .  A m o n t h  
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before he came to the University of Michi- 
gan he had been hospitalized in New York 
City with similar though somewhat less 
marked complaints and had been released 
without a diagnosis, t te  gave no history of 
dysentery or diarrhea. If anything, he felt 
that he had had some constipation in the 
recent past. Physical findings were linfited 
to a remarkable hepatomegaly with liver 
tenderness. Barium studies were not help- 
ful. Liver function tests showed only mild 
abnormalities. Scans and selective angiog- 
raphy delineated space-occupying lesions 
in the liver, which on aspiration, contained 
typical pus. The  patient responded prompt- 
ly to metronidazole. He encountered some 
complications later, but has since recovered 
and has done extremely well. 
These sporadic kinds of outbreaks, 
whether they are epidemics or single cases, 
keep alive in our own environment the 
clinical speculation that amebiasis is some 
kind of sleeping evil which, given the prop- 
er circumstance, can be re!eased into the 
population. There  are less frightening al- 
ternative observations that can be made in 
the light of a 2% incidence of ameba. 
Intestinal amebiasis presents in several 
different ways. When there is amebic dysen- 
tery, with passage of exudate and blood 
rather than feces in the stool, the laborato- 
ry will report that there are large, motile, 
red-celt containing trophozoites that hav ~- 
a characteristic E histolytica nuclear mor- 
phology. If there is diarrhea with stools 
containing exudate and blood in addit.;on 
to feces and again characteristic ameba on 
microscopic examination, it is relatively 
easy to make a diagnos:s of amebic co!itis. 
Few if any supplementary studies would be 
necessary before beginning treatment. 
These presentations are rare in our envi- 
ronment. When a patient presents with 
symptoms that are nonspecific or fimction- 
al and the laboratory reports only the 
presence of characteristic cysts, then a diag- 
nosis of a carrier state can be made. The 
decision to treat the patient may not be ~o 
easily justified. Most hospital laboratories 
report the finding of amebae far less tye- 
quently than a 2°/o incidence of infection 
would suggest they should, in part because 
cysts in a carrier state may be few in 
number  and may be shed irregularly in the 
stool, and in part because of unfamiliarity 
or inexperience in the laboratory. This 
review of the current status of our under- 
standing of ameba infection will hopefully 
offer some perspective for deciding how 
zealously one should look for amebae in 
any individual and what to do when a 
carrier is found. This is a story which is 
still developing and I will try to indicate 
the areas which remain speculative. 
Classically in the United States, physi- 
cians are taught that all strains of E kis- 
lolytica have pathogenic potential and are 
all morphologically distinct from other 
amebae which are parasitic in man. Thus  E 
histolytica (:an be identified solely by look- 
ing at it under the microscope. There have 
been workers in this country and abroad 
who have taken issue with one or both of 
those statements, yet the statements survive 
in the standard texts (3,4). The  clinical 
derivative from the dictum that all E his- 
tolytica are potentially pathogenic is that 
when true E histol),tica is diagnosed in a 
patient, he must be treated; he harbors a 
pathogen. The  clinical derivative of the 
second dictum is that microscopic examina- 
tion of the stool is an adequate mode of 
diagnosis. Both of these statements have 
been more rigorously challenged and it is 
tim development of this challenge that I 
would like to present. If the newer under- 
standing of amebiasis is confirmed, it will 
change the clinician's response to a patient 
with ameba infection. By chance thi~ has 
occurred at a time when a new and success- 
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ful therapy tot amebiasis has been intro- 
duced which ~ompletes the change in the 
clinical picture of this disease. 
The  early histor} of amehiasis was dis- 
cussed by Elsdon-Dew (5) from whose work 
this summary was drawn. Chronologically, 
clinical amebiasis began with Losch who 
was a clinical assistant in St. Petersburg, 
Russia. In 1875, he observed motile amebae 
containing red cells in the stools of a Rus- 
sian peasant who had diarrhea. He later 
performed an autopsy on this pat ient  and 
he was able to identify active amebae in 
colonic ulcers. He inoculated dogs with 
ameba-containing stool and produced 
dysentery in 1 dog. When  the dog died, 
there were motile amebae present in colonic 
ulcers. After Losch's description, there was 
a host of descriptions of E histolytica; after 
some stress among investigators, it wa:s 
finally differentiated from the other proto- 
zoan parasites of the GI  t r ac t - -E  coli, I 
butschii, E nana and D Fagilis. Initially, 
E histolytica was thought  to be an invasive 
parasite that lived only in the presence of 
host tissues. Kunen and Swellengrebel pos- 
tulated in 1913 that there could be a con> 
mensal phase of E histolytica called the 
minuta  stage. 
A second investigator, Dobell  (6), took 
an opposite view. He wrote a book enti t led 
The Amoeba Living In Man, published in 
1919. I t  is this part icular  document  that  is 
carried through the l i terature to us today. 
It was Dobell 's impression that  the ameba, 
as an obligate cellular parasite, was in a 
kind of balanced equi l ibr ium with the in- 
testine--ie,  cellular disso'.ution was bal- 
anced by regeneration and replacement  of 
intestinal tissue. This  impression of the 
ameba as an obligate cellular parasite in 
equi l ibr ium with its host was strengthened 
by the failure to establish ameba in an in 
vitro culture. In 1925, however, a reproduc- 
ible culture technic was found, and it was 
seen that ameba could grow in tile al)sence 
of mammal i an  ce,ls. 
There  emerged from these findings a 
divergence of opinion about  the pathogen- 
ic potent ial  of amebae,  in particular,  con- 
cerning virulent  an(l avirulent  strains. 
Craig and Faust (7), who exemplified an 
American school of thought,  felt that  ame- 
ba infection always implied a mucosal 
lesion somewhere in the intestinal tract. A 
less extreme, but  similar view, sometimes 
called the Unicist school, proposed that at 
times E histolytica could live as a commen- 
sal. (A commensal  is defined as a mess- 
mate, as someone who eats with you and 
doesn' t  eat you.) However,  all E histolytica 
belonged to a single race of potentially 
pathogenic amebae. T h e  differences in be- 
havior in ameba infections were explained 
by these investigators as being due to ex- 
trinsic factors such as host resistance, diet 
and the microenvi ronment  in the intestinal 
tract. This  viewpoint  remains represented 
in the s tandard medicine textbooks to this 
day (3, 4). I t  should be clear that  the exter- 
nal environment ,  the intestinal microenvi- 
ronment ,  and the host response play a very 
fundamenta l  role in the outcome of any 
experience with E histolytica, but  this is 
distinct from or adds to the question of 
intrinsic pathogenicity. Elsdon-Dew jus- 
tifies the role of external  factors in South 
Africa where there is a single pool of 
ameba to which three culturally distinct 
groups are exposed. T h e  u rban  Bantu 
come down with a fu lminat ing  infection, 
amebic dysentery. T h e  East Ind ian  popula-  
tion presents essentially as carriers and the 
Europeans in this env i ronment  have ra ther  
infrequent  clinical infections. T h e y  all 
have a relatively heavy common exposure. 
These Promethean  and Unicist schools, as 
they were called, recognized a single strain 
of ameba that  had a pathogenic potential .  
Since 1925 there has been another  group 
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called the Dualists (9). This  group  differen- 
tiates what we call E histol),tica into two 
species. One species they called E dis]oar, 
and the other, E dysenteriae. E dis]oar is 
thought  to be a commensal  parasite. T im 
second parasite, E dysenteriae, could live as 
a commensal,  but it retains a pathogenic  
potential.  B rumpt  (9), whose ideas these 
were, founded these conclusions on clinical 
and epidemiologic experience and it is a 
system that fits the picture. Unfo r tuna t ey ,  
E dysenteriae in its commensal  phase and E 
dis]oar are, or were said to be, morphologi-  
cally identical, thus being indistinguishable 
by exclusively microscopic methods of diag- 
nosis. This  concept was impossible to apply 
clinically, though it did st imulate other 
workers, part icularly Neal (10), who de- 
veloped Brumpt ' s  thesis, by using animal  
inoculat ion to test the virulence of ameba. 
They  felt that they could demonstrate  two 
types or races of E histolytica, one which 
was invasive and would cause disease and 
the other  which was not. Whe:se characteris- 
tics were, they thought,  related to h u m a n  
disease. T h e  strain characteristics were par- 
tially fixed and bred true in culture, but  it 
was not felt that these characteristics alone 
were of sufficient status to separate the two 
kinds of amebae into two different species. 
They  postulated in effect morphological ly 
identical races, one which was invasive and 
one not, but  could not exclude transitions 
from one group to the other. 
In 1957, Burroughs (1) established the 
now well accepted separation of E hart- 
rnaniz from E histolytica. E hartmanii is 
thought  to be a nonpathogenic  ameba, 
though its pathogenicity has not been sub- 
jected to exhaustive testing. It  is distin- 
guished from E histolytica on the basis of 
cyst size, nuclear morphology and also by 
serology. Superficially, it is similar to E 
hislolytica in appearance,  and prior  to its 
separation from E histolytica, was probably 
always identified as E histolytica. This  ob- 
scures much of tile epidemiologic work 
prior  to 1957 which undoubtedly lumped 
these two together. We emerge with three 
incompatible,  mutual ly  exclusive clinical 
pathologic identifications of ameba, each 
one vigorously defended by competent  and 
well recognized authorities. I[s the last 10 
years, a substantial  body of new inforsna- 
tion' tends to support  the Dualist school of 
interpretat ion.  T h e  new information is pre- 
liminary; it is an evolving story and still 
needs to be verified. The  following is a 
bit speculative. 
In  1956, Connel noted that an isolate of 
E histolytica, which he called the Laredo 
strain (2), was capable of being cultured at 
room temperature  in addit ion to the cus- 
tomary 37°C. This  was felt to be an oddity 
but  elicited little other comment.  This  
ameba morphological ly resembled conven- 
tional E histolytica. T h e  patient  who 
provided this isolate had a history of diar- 
rhea for 3 years, but  also had a villus 
adenoma in the transverse colon; when this 
was resected, his diarrhea subsided. There  
was no evidence that he suffered invasive 
intestinal amebiasis. Over the last 10 years, 
five more isolates of this low temperature  
strain of parasite (13-15), all from human 
stool, have been reported. T h e  Huff  strain 
clearly came from a carrier (16). The  AG 
and JA strains "came from patients whose 
historic background was inadeqnately de- 
scribed, but  who clearly did not have inva- 
sire intestinal disease (14). T h e  isolate of 
Nelson and Jones (13) and the 403 stra;n 
(15) were stated to have come from carriers. 
All have been subjected to careful scrutiny 
and are morphological ly identical with 
classic E histolytica, though they are readi- 
ly separable in the laboratory by nmnipu- 
lating the culture temperature.  
This  group of amebae was awarded the 
designation of Laredo-like E histolytica at 
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the Eighth International Congress of Trop-  
ical Medicine and Malaria. There  have 
accumulated extensive studies that demon- 
strate a number of points of difference 
between the classic ameba and the Laredo- 
like ameba. These have been reviewed by 
Goldman (17) and are summarized below. 
The temperature differential has been 
reconfirmed. True  E histolytica in continu- 
ous culture has a min imum temperature 
requirement of at least 30°C. The  Laredo- 
like ameba can be continuously maintained 
at temperatures as low as 10°C. The  opti- 
mum temperatures are 37 ° for the classic 
and 25-30 ° for the Laredo-like ameba. 
Classic E histolytica cannot be maintained 
in any but an isotonic medium. Dilution of 
the medium by as little as 1 to 2 with dis- 
tilled water will cause the cultures to die 
out. The  Laredo-like ameba can not only 
survive but it can ~-ow in a medium diluted 
as much as 1 to 64 with distilled water. 
This offers another differential test that 
could be used in a bacteriology laboratory. 
There are substantial numbers of other 
biochemical differences between these two 
amebae. Drug sensitivity studies reveal that 
the Laredo-like ameba is more resistant to 
the usual amebacidal drugs than the classic 
strain. There are quantitative differences 
in the free amino acid composition and 
there have been differences demonstrated 
in the isoenzyme patterns. 
In addition to the biochemical differ- 
ences, there are a number of immunochem- 
ical comparisons o[ classic and Lqredo-like 
amebae. All of them show the presence of 
shared antigens, but  there are a sufficient 
number of antigenic differences to permit 
the separation of classic from Laredo-like 
ameba by immunologic means. The  meth- 
ods of comparison have included fluores- 
cent antibody technics, agar diffusion 
studies and hemagglutination studies. 
Not all information has been in support 
of differences of the two groups. No differ- 
ence ill carbohydrate utilization in (u ture 
has been found. There is a single unpab- 
lished report of the laboratory demonstra- 
tion of exchange of genetic material be- 
tween amebae of the two groups based on 
drug resistance as a genetic marker (18). 
Presumably, amebae capable of exchanging 
genetic material cannot be separated as 
species. It  should be noted that the nega- 
tive studies are unconfirmed and the evi- 
dence continues to support  the differences 
between these two groups. 
What  elevates these apparent  biologic 
differences between classic and Laredo-like 
ameba to clinical significance are studies of 
the pathogenicity of the parasite. As indi- 
cated, no isolate of Laredo-!ike ameba has 
clearly come from an individual who 
suffered acute intestinal or systemic am~bi- 
asis. All bave come more or less clear!y 
from carriers. One strain was sqbjecte:l to 
the most strenuous clinical test of path- 
ogenicity that any ameba has been sub- 
iected to. Prior to its identification as a 
Laredo-like ameba, the Huff strain was 
selected for a clinical trial of an induced 
ameba infection in human volunteers (16). 
The  Huff strain was given to 130 prisoner 
volunteers by oral ingestion of cysts. 
Eighty-one of the volunteers were success- 
fully infected, as evidenced by the continu- 
ous passage of cysts in their stools. Of the 
group of 81, no individual was symptomat- 
ic in spite of the passage of ameba in the 
stool. The  clinical evaluation of these pa- 
tients included sigmoidoscopy. A variety of 
animal inoculations have been carried out 
with uniform demonstration of a low or 
negligible pathogenicity of the Laredo-like 
ameba in all cases. There  is some overlap 
between the classic and Laredo-like ameba 
strains in terms of their virulence in ani- 
mals other than man. 
Considering the criteria which distin- 
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guish the Laredo-like ameba fronl the clas- 
sic strain, the differences are substantial  
enough to suggest that the l.aredo-_ike 
ameba may be a separate species. This  
would in effect make then1 the equiwdent  
of Brumpt ' s  nonpathogenic  E dispa.r. This  
has not been done because of the paucity of 
isolates of low tempera ture  strains. The re  
have been only six isolates thus far report- 
ed. In terms of numbers,  the evk!ence is 
not yet overwhelming enough to perm:t  
the establishment of a new species. T h e  
next  step from the clinical s tandpoint  is 
reasonably clear. T h e  parasitologist has 
handed the clinician an attractive l)ath - 
ophysiologic scheme which could explain 
the clinical appearance of ameba infection; 
this scheme needs to be validated. In effect, 
it is ready for clinical trial. An exhaustive 
re-evaluation of the efficiency of cultural 
methods for the diagnosis of ameba infec- 
tions is required. We are currently no mo:e  
justified in accepting microscopic examina- 
tion of the stool for the diagnosis of E 
histolytica than we would be in restricting 
ourselves solely to the Gram stain of a 
sputum smear for the diagnosis of pneumo- 
nia. Clinical microscopy is useful and has a 
place in both circumstances, but  it may be 
insufficient when taken alone. As a second 
step, we will need to identify the biologic 
characteristics of the amebae that infect at 
least 1-2% of our  local populat ion.  Third-  
ly, we need to confirm the consistency of 
the various biologic characteristics among 
more isolates of the low tempera ture  strain. 
Finally, we need a clinical correlation be- 
tween the presence of symptoms and the 
strain of ameba apparent ly  responsible in 
an a t tempt  to confirm avirulence of the 
Laredo-like group. With  the informat ion 
incomplete, it is difficult to justify not 
offering t reatment  if one finds somebody 
with an E histolytica infection. However,  
there is a revolut ionary new approach to 
SODEMAN 
the diagnosis and clinical decision about 
therapy which is clearly just before us. If  
tile in[ornlation which 1 have reviewed is 
validated, then amebiasis will be stripped 
of its mystery and permit ted to find its own 
proper  place among gastrointestinal infec- 
tious diseases. 
i f  and when it finds this place, one 
expects that there will remain some infec- 
tions to treat. Just  as there is currently a 
new unders tanding that threatens our cur- 
rent concept of clinical amebiasis, there are 
significant, virtually revolntionary ad- 
vances in therapy which press in on our 
established regimens. Here  the contest is 
less emotionally charged, since truly effec- 
tive therapy of low toxicity, until  now, has 
been lacking. Wha t  follows is a review of 
the efficiency and tolerance of the common- 
ly employed intestinal and sDtemic ame- 
bacides to provide the framework within 
which the new offerings may he judged. As 
the spectrum of pharmacologic behavior 
unfolds, the rat ionale for acceptance of the 
newer preparat ions should become much 
clearer. 
Emetine is the baseline drug again:t 
which other drug activities are measured. 
I t  is the oldest known effective amebacide. 
I t  has been found useful in both intestinal 
and systemic ameba infection. Its earliest 
use was in the t reatment  of dysentery (19). 
An alkaloid extracted from a plant which 
is indigenous to South America. it was 
taken to Europe in 1658. It  led a rather 
checkered and secret career, and at one 
point, was sold to the French government  
as a secret remedy. I t  didn ' t  achieve signifi- 
cant use until  1858 and the classic paper  
describing its effectiveness was that of Leon- 
ard Rogers in 1912 (20). The  drug remains 
in widespread use today. 
Emetine affords p rompt  relief of symp- 
toms in acute amebiasis al though it is 
ineffective in terms of parasito 'ogic cure. It  
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seems to be more effective in extraintest- 
inal amebiasis, perhaps because it is con- 
centrated in the liver, which is the usual 
site of extraintestinal involvement. Rep- 
resentative results in invasive intestinal 
amebiasis--ie, amebic dysentery--are  5ao¢ /O 
successes, 28 °: absolute failures and 22~o , o  
probable failures (21). A success is a patient 
that is symptom-free and parasite-free. An 
absolute failure is a patient whose symp- 
toms have not improved, and in whom 
parasites and ulcers in the rectum are still 
present. A probable failure is a patient 
whose symptoms have improved but whose 
ulcers remain. 
These results are drawn from the work 
of the Amebiasis Research Uni t  in Durban, 
South Africa (21). Although va.ious ame- 
bacides have been widely tested and report- 
ed, the subsequent discussion will be based 
on the data reported by this single unit. 
The  compilation is based on a number  of 
separately published studies, but  they have 
all been performed by a single group of 
investigators who explicitly at tempted to 
achieve maximum uniformity in their drug 
test program. They  represent, then, the 
most reliable body of comparative informa- 
tion concerning amebacidal drugs. 
The  clinical dissatisfaction with emetine 
steins not only from its rather mediocre 
performance in terms of parasitologic cure 
but also from its substantial toxicity. Eme- 
tine is a protoplasmic poison with a direct 
effect on muscular and nervous tissue (22). 
It is excreted slowly, and the effect may be 
cumulative if its administration is too rap- 
id. The  incidence of reported untoward 
reactions is high if the dosage is adequate 
and the observation complete. In one 
study, 91 of 96 patients experienced some 
side effect (23). Within the safe dose range, 
one may expect myocardial changes such as 
increase in heart rate, decrease in systolic 
pressure and evidence of T wave inversion 
oil the electrocardiogram (24). In addition, 
encephalitis, paralysis and Herxheimer-like 
reactions have been reported. With  this 
drug as a scale, it is possible to turn to the 
comparative value of the other  common 
amebacides that we use. 
Some classes of drugs are active in intes- 
tinal infection; diodoquin (5, 7 diiodo 8 
hydroxyquinoline)  is representative of the 
first general category of these. It has low 
toxicity, most frequently manifested as io- 
(line sensitivity. It has no better effect than 
emetine, with 58~' o success, 24~o failure 
and 18~o probable failure rate (21). It is a 
contact or luminal  drug. Th e  dose is 0.65 g 
orally three times daily for 21 days. 
Representative of the next  class of drugs 
are the arsenic preparations, carbarsone 
and Milibus. Carbarsone's dosage is 0.25 g 
three times a day for 10 days. This  is the 
largest dose which can be tolerated without  
a prohibit ive incidence of reactions. T h e  
toxicity is arsenic poisoning and includes 
nausea, vomiting, convulsions, skin rash, 
exfoliative dermatitis, cramps, diarrhea 
and occasionally jaundice (25). It is not 
significantly more effective than emetine 
(21). 
Milibus contains arsenic and bismuth. Its 
dosage is 0.5 g three times a day for 7 days. 
The  toxicity is generally similar to c a r -  
barsone, although the margin of safety may 
be a little greater (24). It  is substantially 
less effective than emetine (21). 
Entamide furoate (diloxanide furoate) is 
not available in this country, but  has been 
widely used in tropical Africa. T h e  do~age 
is 4 g daily for 10 days. It seems to be an 
effective drug in both the acute intestinal 
disease and in the carrier state. Cure rates 
in some hands have ranged as high as 80~ ,  
tltough the South African group's success 
rate in amebic dysentery was in the range 
of 40~%. Toxici ty  is mi ld--most ly  tingling 
and the development of flatulence. It  corn- 
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pares favorably with emetine and is a sim- 
pler drug to administer  (26). 
Chloroquine is not usually thought  of as 
an intestinal drug; it is a systemic ame- 
bacide. I t  has little effect on intestinal 
infections. T h e  South African group could 
only get a 10~o cure rate with this particu- 
lar drug (21). 
Paromomycin  is a nonabsorbale,  broad 
spectrum antibiotic isolated from strepto- 
myces. In  addit ion to its antibacterial  prop- 
erties, it is thought  to have an ant iamebal  
action. T h e  use of antibiotics in amebiasis 
is based on an indirect effect of the antibi- 
otic altering the bacterial flora and modify- 
ing the apparent ly  delicate ameba-bacterial  
relationship. Any direct amebacidal  action 
of this part icular  drug then is a furth_r 
wduable factor. T w o  grams a day for 10 
days is the usual dose. T h e  toxicity is that  
common to all antibiotics that disturb the 
intestinal flora. I t  is an effective therapy 
with a success rate of 80~,. I t  is more 
effective in acute intestinal disease than in 
the carrier state (26, 27). 
Tetracycl ine is representative of the ab- 
sorbable broad spectrum agents. T h e  dos- 
age commonly  employed was 0.5 g four 
times a day for 10 days. Unti l  recently, the 
broad spectrum antibiotics have been the 
drugs of choice for acute intestinal amebi- 
asis in most tropical areas. They  are oral 
agents with a high degree of effectiveness in 
comparison with emetine, and with a low 
toxicity. However,  their cost may be high. 
Relapse rates are also high. Th i s  is a late 
relapse, suggesting that the drug effect may 
I)e more suppressive than curative. For this 
reason, it is often given in conjunct ion 
with a contact anaebacide such as dio- 
doquin.  T h e  immediate  success rate is 97°{, 
in the hands of the South African group 
(26). Toxici ty  includes alteration of the 
intestinal flora and sensitivity reactions. 
The re  are also problems with the deposi- 
tion of the drug in the enamel of the teeth 
in children, though a short course should 
not cause this problem. The  use of out- 
dated tetracycline should be completely 
preventable.  Clearly, tetracycline is the 
drug that any new prepara t ion will have to 
beat in terms of its utility. Factors of cost, 
mode o1 administrat ion and toxicity are its 
weak points. 
This  brings us to metronidazole. At this 
time, metronidazole is the most effective, 
least toxic intestinal amebacide available 
(28-32). I t  is coupled with a potent systemic 
action. T h e  effective close remains to 1)e 
clarified. For acute intestinal infection, the 
current  recommendat ion is 750 rag, three 
times a day for 5 (lays (29). A number  of 
regimens using fewer, larger doses have 
been stu(lied, and are of part icular  interest 
when patients will not return for follow- 
up. In our environment ,  this particular 
approach,  a 5-day course, has so few side 
effects that it is probably  the program of 
choice. T h e  toxicity includes nausea, vomit- 
lug, dizziness, urticaria and a metallic taste 
in the month  usually with higher doses of 
the drug. The re  is an untoward reaction 
after ingestion of alcohol, which has been 
reported in some patients who receive the 
drug. I t  is a nitroimadozole derivative, it 
does cause leucopenia, and at this time it is 
contraindicated in blood dyscrasias. It  has a 
central nervous system toxicity in some 
animals; at this time. it is %lt that it should 
l)e withheld in patients with organic cen- 
tral nervous system iUness until  this area of 
the drug  activity is better  understood. Since 
the range of toxicity is different, it is diffi- 
cult to compare  it with that of emetine an(1 
tetracycline; however, the impression is 
that the toxicity of metronidazole is milder. 
As an anaebacidal therapy, it appears to 
have a clear advantage since relapse rates 
seen with tetracycline have not been re- 
ported. Success rates from 86 to 955~ ~ have 
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been consistently reported.  Cur ren t ly  it is 
the drug  of choice. 
In  tile t rea tment  of amebic abscess, eme- 
tine is once again the yardstick against 
which the other  drugs mus t  be measured. 
T h e  success rate of emet ine  in the hands  of 
the South African g roup  f rom w h o m  these 
data have been derived is 100~o (33), b u t  it 
should be noted that  these figures are for a 
double  course of the drug. W i t h  a single 
course of the drug,  they have a relapse rate 
of 7 .7~ .  T h e  toxicity' is the same as for its 
use in intestinal disease. 
Ch lo roqu ine  is a highly, effective d rug  in 
systemic amebiasis with a substant ial  ad- 
vantage over emet ine because of its lower 
toxicity. Given as a single course of 150 mg 
two times a day over 30 days after a load- 
ing dose, the success rate for ch lo roqu ine  
,- oe (33). An  absolute fai lure here alone is t2/o
is an instance where a pat ient ' s  condi t ion  
deteriorates du r ing  the 30-day course on  
the drug, and it is t hough t  that  one  mus t  
then intervene with emetine.  T h e  toxicity 
includes retinal lesions, skin erupt ions,  in- 
c luding a psoriatic-like erupt ion ,  nausea, 
dizziness, and in a few people, psychic 
st imulation.  However ,  ch lo roqu ine  used in 
this manne r  rarely presents a significant 
toxicity problem. 
T h e  failure of ei ther  emet ine  or  chloro- 
quine  alone to give 100% success with a 
single course of admin is t ra t ion  p r o m p t e d  
the South African g r o u p  to try combina-  
tion therapy. W i t h  this approach,  a single 
course of each d rug  is adminis tered concur-  
rently. Success with this reg imen is excel- 
lent, and unti l  recently, this has been  the 
therapy of choice for amebic  abscesses (34). 
Metroniadazole  then came on the scene. 
Once again this proved to be the most  
potent,  least toxic d rug  for systemic ameba  
infection that  has yet been described. T h e  
m i n i m u m  dose in systemic amebiasis has 
yet to be determined.  T h e  South  Afr icans 
use 800 mg three times a (lay for 5 days. 
T h e  best local equiva len t  is 75(1 mg sin(c 
the drug  is fo rmula ted  in a 250-rag tablet  
in this country,  aud ill :1 200-lUg tab.or 
outside of this country.  I n  the South Afri- 
can group,  and in others,  this has been 
100~{0 effective in t reat ing amebic  ab:~cess 
(28, 29). In  the few patients we have had an 
o p p o r t u n i t y  to treat at the Univers i ty  of 
Michigan,  we also have had  1 0 0 ~  success. 
Single large doses have been trie:l with 
success bu t  with some a t t endan t  toxicity, 
usually in the form of vomi t ing  at the dose 
level adminis tered.  
I n  summary ,  wha t  we treat, w h o m  we 
treat, with what  agent  we treat ameba  
infect ion all have unde rgone  recent  and 
substant ial  change.  For  those who have 
been separated f rom the evolu t ion  of re- 
cent  in format ion ,  amebiasis presented in 
this way at this time has the appearance  of 
a new disease. 
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